Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYANAVEL XR 20 vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
FDA-approved: Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.,Off-label: Treatment-resistant depression, narcolepsy (though individual components are approved for narcolepsy, DYANAVEL XR as a specific formulation is not).
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Terminal elimination half-life: 6-8 hours (stable metabolite). Clinical context: Twice-daily dosing typical due to pharmacokinetic profile; extended half-life compared to immediate-release amphetamine.
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Amphetamine is metabolized primarily by CYP2D6 and also by CYP2C19 and CYP3A4 via deamination, oxidation, and conjugation. The active metabolites include 4-hydroxyamphetamine and norephedrine. Genetic polymorphisms in CYP2D6 may affect metabolism and drug levels.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: 90% (unchanged drug and metabolites, primarily hippuric acid). Fecal/biliary: <1%.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
15-40% bound to albumin.
16% (primarily albumin).
3-5 L/kg (indicates extensive tissue distribution; crosses blood-brain barrier).
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral (extended-release): 95% (high bioavailability; minimal first-pass metabolism).
Oral IR: ~90%; ER: ~90%.
GFR 15-29 m L/min: maximum 40 mg/day; GFR <15 m L/min or dialysis: not recommended.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
Ages 6-17: initial 10 mg once daily; may increase by 5-10 mg weekly to max 30 mg/day for ages 6-12, max 40 mg/day for ages 13-17.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Initiate at 10 mg once daily; lower doses may be required due to renal function decline; monitor for cardiac effects.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
DYANAVEL XR has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events. It should be prescribed cautiously, especially in patients with a history of substance abuse.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported, especially in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor vital signs regularly.,Psychiatric adverse events: May exacerbate pre-existing psychosis, mania, or aggression; caution in patients with bipolar disorder or history of psychosis.,Seizures: May lower seizure threshold; use cautiously in patients with seizure disorders.,Peripheral vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.,Serotonin syndrome: Risk when co-administered with serotonergic drugs.,Growth suppression: Long-term use may slow growth in children; monitor height and weight.
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Hypersensitivity to amphetamine or any component of the formulation.,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis.,Hyperthyroidism.,Agitated states.,Glaucoma.,History of drug abuse.,Cardiovascular disease: Moderate to severe hypertension, advanced arteriosclerosis, symptomatic coronary artery disease, structural heart abnormalities, cardiomyopathy, serious arrhythmias, or other serious cardiac conditions.
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
Avoid high-fat meals around the time of administration as they may delay absorption and reduce peak concentration. Limit caffeine intake (coffee, tea, soda, energy drinks) as it can exacerbate nervousness, insomnia, and cardiovascular effects. No specific food restrictions otherwise.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
Pregnancy Category C. There is no adequate and well-controlled study in pregnant women. In animal reproduction studies, amphetamine (dextroamphetamine/amphetamine) at doses up to 41 times the maximum recommended human dose of 20 mg/day (based on mg/m²) produced no teratogenic effects; however, increased neonatal mortality and reduced growth were observed at maternally toxic doses. In humans, retrospective studies have reported a higher incidence of premature delivery, low birth weight, and withdrawal symptoms (e.g., dysphoria, agitation, lassitude) in neonates exposed to amphetamines during the third trimester. There is also a potential risk for cardiovascular malformations if used in the first trimester. Therefore, the drug should be used only if the potential benefit justifies the potential risk to the fetus.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Amphetamines are excreted into human milk. The milk-to-plasma concentration ratio for amphetamine is approximately 1.8 to 5.9. A nursing infant would receive 4-10% of the maternal weight-adjusted dose. There are reports of irritability, poor feeding, and decreased weight gain in infants exposed to amphetamines via breast milk. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
Pregnancy may alter the pharmacokinetics of amphetamines due to increased plasma volume, renal blood flow, and hepatic metabolism. The elimination half-life may be shortened, requiring dose adjustments. However, no specific dosing guidelines are established for pregnancy. Use the lowest effective dose, and monitor clinical response and tolerability. Postpartum doses may need to be reduced to pre-pregnancy levels.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
For patients with attention deficit hyperactivity disorder (ADHD), initiate at 20 mg once daily in the morning; may increase by 10 mg weekly to a maximum of 60 mg/day. Contains immediate-release and extended-release beads; avoid crushing or chewing. Monitor for hypertension, tachycardia, and growth suppression in children. Use with caution in patients with pre-existing cardiovascular disease or seizure disorder. Do not co-administer with MAOIs or within 14 days of discontinuing an MAOI.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take exactly as prescribed, usually once daily in the morning to avoid insomnia.,Swallow capsules whole; do not crush, chew, or open them.,Avoid alcohol and caffeine-containing products as they may worsen side effects.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.,Report any chest pain, shortness of breath, or fainting immediately.,For children, height and weight will be monitored during treatment.,Do not stop abruptly without consulting your doctor; dosage may need to be tapered.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYANAVEL XR 20 vs ADDERALL 20, answered by our medical review team.
DYANAVEL XR 20 is a CNS Stimulant that works by DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYANAVEL XR 20 and ADDERALL 20 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYANAVEL XR 20 is: Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYANAVEL XR 20 and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYANAVEL XR 20 is classified as Category C. Pregnancy Category C. There is no adequate and well-controlled study in pregnant women. In animal reproduction studies, amphetamine (dextroamphetamine/amphetamine) at doses up to 4. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.